Presentation: Emerging Non-viral Modalities

December 4, 2024 by Aldevron

Changing up approaches to cell and gene therapy manufacturing

As the cell and gene therapy field has continued to advance, so have the manufacturing modalities developers apply in their pipelines. In his talk Enabling Emerging Non-viral Modalities for Gene and Cell Therapies, given at Biotech Week Boston, Patrick Paez discussed how CDMOs such as Aldevron aid developers with emerging non-viral manufacturing options.

Using recent reports, publications, and clinical studies, Paez provides specific examples of how Aldevron’s products and services have enabled clients in their CRISPR and transposon-based therapies. Topics covered included:

• Nanoplasmid^TM, a next generation plasmid vector system for cell and gene therapy applications used in both transposon and CRISPR workflows
• mRNA-based delivery methods and end-to-end manufacturing services at Aldevron for non-viral manufacturing modalities
• Novel Cas nucleases for CRISPR gene editing like Spy Fi^TM Cas9
• A first-in-class RNP* analytical service for developers designed to meet the FDA’s current recommendations.

• Visit our Nanoplasmid page
• Learn more about our mRNA products and services
• Get more information on our CRISPR gene editing services
• Have questions on this topic? Contact Us
• Have an idea for a topic? Let us know!

*Aldevron provides RNPs only to customers who are duly licensed, including to make and have made RNPs, for their intended use.

Subscribe to our blog